LDOC1 (LDOC1 regulator of NFKB signaling) functions as a tumor suppressor that negatively regulates NF-κB signaling and inflammatory responses. Primary function: LDOC1 localizes to the nucleus and nucleoplasm 1 and acts as a negative regulator of NF-κB-mediated transcription across multiple cancer types 23. Mechanism: LDOC1 suppresses NF-κB activation by reducing nuclear P65 expression 23. In oral pathogenesis, LDOC1 inhibits oral microbe-induced IL-1β production through the PI3K/Akt/pGSK-3β signaling pathway 4. In NSCLC, LDOC1 interacts with histone H2B and H2Bub1 to regulate chrX compaction and control metastasis-related genes involved in epithelial-mesenchymal transition 1. Disease relevance: LDOC1 is downregulated in papillary thyroid carcinoma 32, osteosarcoma 5, ependymoma 6, and NSCLC. Loss of LDOC1 increases tumor cell proliferation, invasion, and metastasis while suppressing apoptosis 325. Clinical significance: Higher LDOC1 expression correlates with improved overall and disease-free survival in osteosarcoma patients 5. LDOC1 represents a potential prognostic marker and therapeutic target in multiple malignancies.